Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21078285 | 0.87 | NAMPT (0.64) | NAMPTSIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL17888382 | 0.83 | GABRD (0.57) | NAMPTHPGDL3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL30634133 | 0.80 | HPGD (0.56) | HPGDALDH1A1TSHR | |
| SCHEMBL14742135 | 0.80 | NAMPT (0.66) | NAMPTSIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL23071019 | 0.79 | TSHR (0.58) | NAMPTCHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19226561 | 0.79 | HPGD (0.60) | NAMPTHPGDL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL11713669 | 0.79 | SIGMAR1 (0.51) | SIGMAR1CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7170178 | 0.78 | NAMPT (0.67) | NAMPTSIGMAR1L3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL6631344 | 0.78 | HSD17B10 (0.67) | NAMPTSIGMAR1HPGDL3MBTL3L3MBTL1 | |
| SCHEMBL3699920 | 0.77 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-9157077-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2516425-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-9073903-B2 | Imidazole-2,4-dione inhibitors of casein kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073903-B2 | Imidazole-2,4-dione inhibitors of casein kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073903-B2 | Imidazole-2,4-dione inhibitors of casein kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-20120316155-A1 | Imidazole-2,4-Dione Inhibitors of Casein Kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316155-A1 | Imidazole-2,4-Dione Inhibitors of Casein Kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316155-A1 | Imidazole-2,4-Dione Inhibitors of Casein Kinase 1 | Jasco Pharmaceuticals, LLC (US) | 2012-12-13 | — | — | US | disclosed |
| EP-2516425-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011103289-A2 | IMIDAZOLE-2, 4-DIONE INHIBITORS OF CASEIN KINASE 1 | Jasco Pharmaceuticals, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079274-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | Jasco Pharmaceuticals, LLC (US) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080799-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | NAMPT 1906/4885SIGMAR1 2801/4885CHRNB2 3873/4885 |
| US-20110152235-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | NAMPT 1943/4885SIGMAR1 2735/4885CHRNB2 3906/4885 |
| US-20120316155-A1 | Imidazole-2,4-Dione Inhibitors of Casein Kinase 1 | CSNK1G1, CSNK1A1, CSNK1G3 | NAMPT 2817/4885SIGMAR1 3638/4885CHRNB2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.